Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Phase 2 Terminated
3 enrolled 11 charts
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Phase 2 Terminated
1 enrolled
Tamarack
Phase 2 Terminated
192 enrolled 20 charts
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Phase 1/2 Terminated
46 enrolled 22 charts
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
45 enrolled 44 charts
RELATIVITY-098
Phase 3 Terminated
1,093 enrolled 15 charts
Pembrolizumab and EDP1503 in Advanced Melanoma
Phase 2 Terminated
8 enrolled 10 charts
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
Phase 1/2 Terminated
34 enrolled 18 charts
PAVO
Phase 2 Terminated
22 enrolled 17 charts
MAVIS
Phase 3 Terminated
504 enrolled 23 charts
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Phase 1 Terminated
65 enrolled 52 charts
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Phase 1/2 Terminated
31 enrolled 12 charts
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Phase 2 Terminated
23 enrolled 15 charts
COMBI-i
Phase 3 Terminated
568 enrolled 28 charts
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Phase 2/3 Terminated
20 enrolled 18 charts
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Phase 1 Terminated
8 enrolled 8 charts
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
Phase 1 Terminated
3 enrolled 9 charts
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Phase 1/2 Terminated
7 enrolled 11 charts
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Phase 2 Terminated
44 enrolled 19 charts
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Phase 3 Terminated
19 enrolled 19 charts
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Phase 2 Terminated
11 enrolled 8 charts
Study of INCB086550 in Select Solid Tumors
Phase 2 Terminated
16 enrolled 17 charts
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Phase 2 Terminated
205 enrolled 54 charts
ATL001 in Patients With Metastatic or Recurrent Melanoma
Phase 1/2 Terminated
13 enrolled 14 charts
PANAMA
Phase 1 Terminated
60 enrolled 22 charts
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
Phase 2 Terminated
1 enrolled 8 charts
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Phase 1/2 Terminated
5 enrolled 6 charts
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
Phase 2 Terminated
4 enrolled 8 charts
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
22 enrolled 21 charts
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Phase 2 Terminated
315 enrolled 73 charts
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
Phase 2 Terminated
1 enrolled 9 charts
PVSRIPO for Patients With Unresectable Melanoma
Phase 1 Terminated
12 enrolled 11 charts
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Phase 2 Terminated
4 enrolled 11 charts
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Phase 2 Terminated
15 enrolled 15 charts
V937-011
Phase 2 Terminated
85 enrolled 19 charts
IL-2
Phase 3 Terminated
1 enrolled 3 charts
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Phase 1/2 Terminated
37 enrolled 30 charts
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
49 enrolled 33 charts
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
QUAD01
Phase 1/2 Terminated
2 enrolled 12 charts
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Phase 1 Terminated
13 enrolled 16 charts
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Phase 2 Terminated
14 enrolled 12 charts
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Phase 2 Terminated
1 enrolled
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Phase 1 Terminated
24 enrolled 29 charts
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Phase 1 Terminated
22 enrolled 14 charts
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Phase 2 Terminated
7 enrolled 4 charts
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Phase 2 Terminated
45 enrolled 14 charts
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
Terminated
2 enrolled 6 charts